Today: 9 April 2026
UnitedHealth stock today: UNH rises after hours as traders look ahead to January guidance
30 December 2025
1 min read

UnitedHealth stock today: UNH rises after hours as traders look ahead to January guidance

NEW YORK, December 30, 2025, 5:05 PM ET — After-hours

  • UnitedHealth shares rose in after-hours trading, outpacing a slightly weaker broader market.
  • Managed-care peers were mixed, with modest gains in Elevance and Humana and a dip in CVS Health.
  • The next major catalyst is UnitedHealth’s late-January results and 2026 outlook update.

UnitedHealth Group shares were up about 1% at $332.16 in after-hours trading on Tuesday, following the 4 p.m. close. The stock ranged from $329.18 to $336.03 during the day’s session, with about 4.4 million shares traded.

The gain came as U.S. stocks ended slightly lower in holiday-thin trading. The S&P 500 slipped 0.14%, the Dow fell 0.20% and the Nasdaq lost 0.23%. Reuters

Investors are repositioning as 2025 winds down, and swings can look sharper when volumes are light. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” said Mark Hackett, chief market strategist at Nationwide. Reuters

Why it matters now for UnitedHealth is what comes next, not just where it traded in a single session. The company has set late January as the next key checkpoint for updated outlook and management commentary.

UnitedHealth said it will release full-year 2025 financial results and provide 2026 guidance on Tuesday, Jan. 27, before the market opens, and host a conference call at 8 a.m. ET. UnitedHealth Group

Among big managed-care names, the tape was steadier than UnitedHealth’s move. Elevance Health was up 0.1% and Humana gained 0.3%, while CVS Health, whose pharmacy-benefits manager negotiates drug prices for health plans, fell 0.2%.

Healthcare broadly lagged the single-stock move. The Health Care Select Sector SPDR Fund, an exchange-traded fund (ETF) that tracks major U.S. healthcare companies, was down 0.1%.

For investors, the late-January update will be a test of whether cost pressures are easing and how UnitedHealth is pricing for 2026. Managed-care stocks have been sensitive to signals around Medicare Advantage, the privately run alternative to the federal Medicare program for seniors.

A key watchpoint is the medical cost ratio, which shows how much premium revenue an insurer spends on medical claims. When that ratio rises, it can pinch profit margins even if membership grows.

Traders will also parse updates from Optum, UnitedHealth’s health-services business, for signs that services growth can offset pressure in the insurance unit. Any comments on utilization trends and pricing discipline are likely to set the tone for the group.

Ahead of the next session, investors expect thin liquidity to persist into year-end, when index and portfolio rebalancing can amplify moves. UnitedHealth’s outperformance versus the broader healthcare ETF on Tuesday underscored how quickly money can rotate inside the sector when market leadership shifts.

Stock Market Today

  • AbbVie's Humira Launch on TrumpRx with 86% Discount Sparks Valuation Questions
    April 9, 2026, 9:02 AM EDT. AbbVie (NYSE:ABBV) has introduced Humira on the TrumpRx platform at an 86% discount under a White House pricing deal aiming to reduce patient costs and widen drug access. This marks a significant US pricing strategy shift post exclusivity for Humira, a key immunology therapy driving substantial revenue. The stock trades near $206.69, about 20% below analyst targets and 43.8% under fair value estimates. The deep discount could alter patient volume, payer ties, and pricing benchmarks in government-linked drug programs. AbbVie's revenue exposure of $61.2 billion and a high price-to-earnings ratio of 87.3 place focus on potential impacts to cash flow and dividends amid its debt load. Investors should monitor reactions from payers, competitors, and capital markets to this pricing shift that could redefine AbbVie's US market dynamics.

Latest article

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

When Will Gas Prices Fall? Iran Ceasefire May Not Bring Quick Relief as Oil Rebounds

9 April 2026
Brent crude rebounded 3% Thursday despite a U.S.-Iran ceasefire, with the Strait of Hormuz still nearly shut and only one oil-products tanker passing in 24 hours. U.S. gasoline averaged $4.166 a gallon on April 9, and AAA said prices could drop slowly. North Sea Forties crude hit a record $146.43 a barrel. The U.S. EIA expects Hormuz flows may take months to recover.
CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

CoreWeave Stock Climbs on $21 Billion Meta AI Cloud Deal, but Debt Risks Stay in Focus

9 April 2026
CoreWeave said Meta Platforms committed about $21 billion for AI cloud capacity through December 2032. Shares rose 4.3% to $88.90 in premarket trading after the announcement. The deal follows an $8.5 billion loan facility and a $1.25 billion senior notes offering. CoreWeave reported $5.13 billion in 2025 revenue and ended December with a $66.8 billion backlog.
NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

NVIDIA’s Rubin AI Chip Ramp Hits Fresh Snag as HBM4 Memory Crunch Clouds 2026

9 April 2026
TrendForce said April 8 that Nvidia’s Rubin AI chip shipments may be delayed by HBM4 memory qualification and cooling demands, shifting over 70% of 2026 high-end GPU volume to the current Blackwell line. Rubin’s projected share dropped to 22%. Samsung began shipping HBM4 to Nvidia in February, but SK Hynix and Micron face qualification delays. Broadcom signed a long-term deal to develop Google’s TPUs through 2031.
AppLovin stock slips after Fed minutes as year-end tech rotation hits APP shares
Previous Story

AppLovin stock slips after Fed minutes as year-end tech rotation hits APP shares

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus
Next Story

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Go toTop